

Jack Bartram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7934284/publications.pdf>

Version: 2024-02-01

51
papers

1,558
citations

361413

20
h-index

315739

38
g-index

52
all docs

52
docs citations

52
times ranked

2815
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. <i>Nature Medicine</i> , 2019, 25, 1408-1414.	30.7	394
2	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019, 33, 2241-2253.	7.2	177
3	Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 34-43.	1.6	147
4	Targeting acute myeloid leukemia by drug-induced c-MYB degradation. <i>Leukemia</i> , 2018, 32, 882-889.	7.2	78
5	Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 660-667.	1.6	76
6	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2254-2265.	7.2	70
7	Persistent defective membrane trafficking in epithelial cells of patients with familial hemophagocytic lymphohistiocytosis type 5 due to <i>STXBP2/MUNC18</i> mutations. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1215-1222.	1.5	59
8	Extracranial internal carotid arterial disease in children with sickle cell anemia. <i>Haematologica</i> , 2010, 95, 1287-1292.	3.5	48
9	Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. <i>Leukemia</i> , 2016, 30, 2312-2321.	7.2	47
10	Blinatumomab for infant acute lymphoblastic leukemia. <i>Blood</i> , 2020, 135, 1501-1504.	1.4	43
11	Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. <i>Blood</i> , 2009, 114, 742-743.	1.4	36
12	Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2022, 28, 743-751.	30.7	35
13	Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 494-506.	2.8	31
14	A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program. <i>Nature Communications</i> , 2021, 12, 6905.	12.8	28
15	High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments. <i>Haematologica</i> , 2018, 103, e110-e114.	3.5	27
16	Outcome of adults with sickle cell disease admitted to critical care – experience of a single institution in the UK. <i>British Journal of Haematology</i> , 2010, 150, 610-613.	2.5	26
17	A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2020, 135, 1438-1446.	1.4	25
18	The "Lasso-o" tape: stretchability and observer variability in head circumference measurement. <i>Archives of Disease in Childhood</i> , 2005, 90, 820-821.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003. Archives of Disease in Childhood, 2016, 101, 449-454.	1.9	22
20	Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia. Archives of Disease in Childhood, 2011, 96, 1082-1084.	1.9	20
21	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. British Journal of Haematology, 2020, 190, e274-e276.	2.5	20
22	Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Seminars in Hematology, 2020, 57, 142-148.	3.4	20
23	Soluble CD163 levels in children with sickle cell disease. British Journal of Haematology, 2011, 153, 105-110.	2.5	12
24	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. Blood Advances, 2020, 4, 4665-4668.	5.2	11
25	MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis. American Journal of Neuroradiology, 2021, 42, 2077-2085.	2.4	11
26	Primary immunodeficiencies and their associated risk of malignancies in children: an overview. European Journal of Pediatrics, 2020, 179, 689-697.	2.7	10
27	Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia, 2022, 36, 1541-1549.	7.2	10
28	Improvements in outcome of childhood acute lymphoblastic leukaemia (ALL) in the UK - a success story of modern medicine through successive UKALL trials and international collaboration. British Journal of Haematology, 2020, 191, 562-567.	2.5	9
29	H-type tracheoesophageal fistula masquerading as achalasia cardia in a 13-year-old child. Journal of Paediatrics and Child Health, 2006, 42, 215-216.	0.8	7
30	Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27787.	1.5	7
31	Blinatumomab for paediatric mixed phenotype acute leukaemia. British Journal of Haematology, 2021, 195, 289-292.	2.5	5
32	Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation. British Journal of Haematology, 2021, 195, 805-811.	2.5	5
33	Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy. Blood, 2021, 138, 1743-1743.	1.4	4
34	High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study. Pediatric Blood and Cancer, 2022, 69, e29513.	1.5	3
35	Combining Genotype Profiling with MRD for More Accurate Prognostication in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S63-S65.	0.4	2
36	Perianal Infections in Children With Acute Myeloid Leukemia: A Report From the Canadian Infection in Acute Myeloid Leukemia Research Group. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 354-357.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Immunoglobulin/T-Cell Receptor (Ig/TCR) Allele Usage in Normal and on Treatment Bone Marrow Samples in Childhood Acute Lymphoblastic Leukaemia - Implications for NGS Based MRD Analysis. <i>Blood</i> , 2016, 128, 4073-4073.	1.4	2
38	ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy. <i>Blood</i> , 2021, 138, 3859-3859.	1.4	2
39	Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7573.	4.1	2
40	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015, 126, 1411-1411.	1.4	1
41	Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD: Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. <i>Blood</i> , 2015, 126, 806-806.	1.4	1
42	Failure of Romidepsin to Treat Relapsed/Refractory Peripheral T-Cell Lymphoma in Children: A Single-center Experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e745-e748.	0.6	1
43	2339. Perianal Infections in Children With Acute Myeloid Leukemia: A Report From the Canadian Infection in Acute Myeloid Leukemia Research Group. <i>Open Forum Infectious Diseases</i> , 2018, 5, S695-S695.	0.9	0
44	ARHGEF4 Regulates an Essential Oncogenic Program in t(12;21)-Associated Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2020, 4, e467.	2.7	0
45	Imatinib for control of bullous skin lesions in a child with familial mastocytosis. <i>British Journal of Haematology</i> , 2021, 194, 945-945.	2.5	0
46	Excellent Outcome Of MRD Low Risk Patients Is Sustained With Greater Than 10 Years Follow Up Results Of UK ALL Trials 1997 -2003. <i>Blood</i> , 2013, 122, 2635-2635.	1.4	0
47	Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial. <i>Blood</i> , 2015, 126, 1412-1412.	1.4	0
48	Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 603-603.	1.4	0
49	Artificial DNA Templates for the Correction of PCR Bias in Next Generation Sequencing Based MRD Analysis for Childhood Acute Lymphoblastic Leukaemia: The Influence of Secondary DNA Structure. <i>Blood</i> , 2016, 128, 4078-4078.	1.4	0
50	Clinical Utility of Radiologic Disease Reassessment in the Management of Pediatric B-Cell Non-Hodgkin Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e380-e384.	0.6	0
51	Recalcitrant transient abnormal myelopoiesis in neonatal Down syndrome. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29662.	1.5	0